血小板糖蛋白II b/IIIa受体拮抗剂在缺血性脑血管病中的应用进展  

A review of platelet glycoprotein II b/IIIa receptor antagonists in ischemic cerebrovascular disease

作　　者：李相军 汤建军 LI Xiangjun;TANG Jianjun(Department of Neurology,Shanghai Neuromedical Center,Shanghai 200331,China)

机构地区：[1]上海德济医院神经内科,上海200331

出　　处：《世界临床药物》2021年第7期528-531,共4页World Clinical Drug

摘　　要：血小板在缺血性脑血管病(ischemic cerebrovascular disease)的发生过程中发挥着关键作用,目前对于该病的主要治疗策略是针对其开展的抗血小板治疗。以往使用的抗血小板药物主要为阿司匹林(aspirin)和氯吡格雷(clopidogrel),但是从目前患者的实际治疗情况来看,一些患者在服用药物后也存在发生急性血栓或栓塞的可能。本文对另外3种目前较为常用的抗血小板药物阿昔单抗(abciximab)、替罗非班(tirofiban)、依替巴肽(eptifibatide)进行了对比分析,并讨论其在缺血性脑血管病患者中的应用。Platelets play a key role in the treatment of ischemic cerebrovascular disease.Currently,anti-platelet aggregation therapy is the main treatment strategy for this disease.The main antiplatelet agents in the past were aspirin and clopidogrel,but from the actual treatment situation of current patients,some patients also have the possibility of developing acute thrombus or embolism after taking medicine.In this review,three other commonly used antiplatelet agents,abciximab,tirofiban and eptifibatide,are comparatively analyzed and their use in patients with ischemic cerebrovascular diseases are discussed.

关 键 词：血小板糖蛋白II b/IIIa受体拮抗剂 阿昔单抗 替罗非班 依替巴肽 缺血性脑血管病 

分 类 号：R743.3[医药卫生—神经病学与精神病学] R973.2[医药卫生—临床医学]